NEW YORK – Genomic testing firm Veracyte reported after the close of the market on Wednesday that its first quarter 2020 revenues grew 5 percent year over year.
For the three months ended Mar. 31, the South San Francisco, California-based molecular diagnostics firm reported total revenues of $31.1 million compared to $29.5 million in Q1 2019, beating analysts' average estimate of $30.6 million.
In addition, Veracyte's testing volumes grew by 15 percent year over year to 10,559 tests.